BIVI: AI 评分 46/100 — AI 分析 (4月 2026)

BioVie Inc. is a clinical-stage biotechnology company focused on developing innovative drug therapies. Their pipeline includes treatments for Alzheimer's disease, Parkinson's disease, liver disease, multiple myeloma and prostate cancer.

Key Facts: Price: $1.40 AI Score: 46/100 Sector: Healthcare

公司概况

概要：

BioVie Inc. (BIVI) is a clinical-stage biotech firm pioneering therapies for Alzheimer's, Parkinson's, and liver diseases, with its lead drug NE3107 in Phase III trials for Alzheimer's, positioning it for significant growth in the neurodegenerative disease market. The company's market cap is $0.01B.

BIVI是做什么的？

BioVie Inc., founded in 2013 and based in Carson City, Nevada, is a clinical-stage biotechnology company dedicated to discovering, developing, and commercializing innovative drug therapies. Originally named NanoAntibiotics, Inc., the company rebranded as BioVie Inc. in July 2016, signaling a strategic shift towards a broader therapeutic focus. BioVie's pipeline features two primary drug candidates: BIV201 and NE3107. BIV201 has completed a Phase IIa clinical trial for treating ascites due to chronic liver cirrhosis, addressing a critical unmet need in liver disease management. The company's lead drug candidate, NE3107, is currently in a Phase III clinical trial for the treatment of mild to moderate Alzheimer's disease, representing a significant opportunity in the growing Alzheimer's therapeutics market. Additionally, NE3107 is in a Phase I clinical trial for Parkinson's disease, expanding its potential applications in neurodegenerative disorders. BioVie is also exploring NE3107's potential in oncology, with preclinical studies underway for multiple myeloma and prostate cancer, demonstrating the drug's versatility and potential across multiple therapeutic areas. With a small team of 14 employees, BioVie is focused on advancing its clinical programs and securing strategic partnerships to drive long-term growth.

BIVI的投资论点是什么？

BioVie Inc. presents a notable market position due to its promising lead drug candidate, NE3107, which is currently in Phase III clinical trials for Alzheimer's disease. Positive trial results could lead to significant market adoption, addressing a critical unmet need in the Alzheimer's therapeutics market. The company's focus on neurodegenerative diseases and oncology provides diversification and multiple potential value drivers. The current market capitalization of $0.01 billion suggests undervaluation, particularly if NE3107 demonstrates efficacy in late-stage trials. Key catalysts include the progression of NE3107 through clinical trials and potential partnerships with larger pharmaceutical companies. Successful commercialization of NE3107 could generate substantial revenue and drive significant shareholder value. The company's P/E ratio is -0.61 and Beta is 0.56.

BIVI在哪个行业运营？

The biotechnology industry is characterized by high-risk, high-reward investments, driven by innovation and the potential for breakthrough therapies. The Alzheimer's disease market, in particular, is experiencing significant growth due to the aging global population and the increasing prevalence of the disease. BioVie's focus on NE3107 positions it to capitalize on this trend. Competitors like ARTL (Artesian Resources Corporation), CANF (Can-Fite BioPharma Ltd), CERO (Cero Therapeutics Holdings, Inc.), ELAB (Elanco Animal Health Incorporated), and GLMD (Galmed Pharmaceuticals Ltd.) operate in various segments of the biotech and pharmaceutical industries. BioVie's success hinges on the clinical trial outcomes and regulatory approvals for its lead drug candidates.

Biotechnology

Healthcare

BIVI有哪些增长机遇？

Alzheimer's Disease Market: The global Alzheimer's disease market is projected to reach billions of dollars by 2030, driven by an aging population and limited treatment options. BioVie's NE3107, currently in Phase III trials, has the potential to capture a significant share of this market if it demonstrates efficacy and receives regulatory approval. The timeline for potential market entry is dependent on clinical trial results and FDA review, with potential launch in 2028 if trials are successful.
Parkinson's Disease Market: The Parkinson's disease market is also growing, with increasing demand for effective therapies to manage symptoms and slow disease progression. BioVie's NE3107 is in Phase I trials for Parkinson's, offering a potential new treatment option. Success in these trials could open up a significant market opportunity, with potential for future expansion and revenue growth. The timeline for potential market entry is dependent on clinical trial results and FDA review, with potential launch in 2030 if trials are successful.
Liver Disease Market: BioVie's BIV201, which has completed Phase IIa trials for ascites due to chronic liver cirrhosis, addresses a critical unmet need in liver disease management. The market for liver disease treatments is substantial, and BIV201 could capture a portion of this market with further development and regulatory approval. The timeline for potential market entry is dependent on further clinical trial results and FDA review, with potential launch in 2029 if trials are successful.
Oncology Applications: BioVie is exploring NE3107's potential in multiple myeloma and prostate cancer through preclinical studies. Success in these studies could lead to new clinical trials and potential entry into the oncology market, providing further diversification and growth opportunities. The timeline for potential market entry is dependent on preclinical and clinical trial results and FDA review, with potential launch in 2032 if trials are successful.
Strategic Partnerships: BioVie can pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its drug candidates. These partnerships could provide funding, expertise, and access to established distribution networks, enhancing BioVie's ability to bring its therapies to market and maximize their commercial potential. The timeline for potential partnerships is ongoing, with potential deals occurring throughout the development process.

BIV201 completed Phase IIa clinical trial for ascites due to chronic liver cirrhosis, demonstrating potential in liver disease treatment.
NE3107 is in Phase III clinical trial for mild to moderate Alzheimer's disease, addressing a significant unmet need.
NE3107 is in Phase I clinical trial for Parkinson's disease, expanding its potential applications in neurodegenerative disorders.
Pre-clinical development of NE3107 for multiple myeloma and prostate cancer, indicating potential in oncology.
Market capitalization of $0.01 billion, suggesting potential undervaluation.

BIVI提供哪些产品和服务？

Develops drug therapies for Alzheimer's disease.
Develops drug therapies for Parkinson's disease.
Develops drug therapies for liver diseases.
Develops drug therapies for multiple myeloma.
Develops drug therapies for prostate cancer.
Conducts clinical trials to evaluate drug efficacy and safety.
Seeks regulatory approvals for its drug candidates.

BIVI如何赚钱？

Develops and patents novel drug therapies.
Conducts clinical trials to demonstrate drug efficacy and safety.
Seeks regulatory approval from the FDA.
Commercializes approved drugs through partnerships or direct sales.

Patients suffering from Alzheimer's disease.
Patients suffering from Parkinson's disease.
Patients suffering from liver diseases.
Patients suffering from multiple myeloma.
Patients suffering from prostate cancer.

Proprietary drug candidates with patent protection.
Clinical trial data demonstrating efficacy and safety.
Experienced management team with expertise in drug development.
Focus on underserved markets with high unmet needs.

什么因素可能推动BIVI股价上涨？

Upcoming: Phase III clinical trial results for NE3107 in Alzheimer's disease (expected in 2027).
Upcoming: Phase I clinical trial results for NE3107 in Parkinson's disease (expected in 2027).
Ongoing: Pre-clinical development of NE3107 for multiple myeloma and prostate cancer.
Ongoing: Potential partnerships with larger pharmaceutical companies.
Ongoing: Regulatory review and potential approval of NE3107.

BIVI的主要风险是什么？

Potential: Failure of clinical trials for NE3107.
Potential: Regulatory hurdles and delays in drug approval.
Ongoing: Competition from other biotechnology companies.
Ongoing: Limited financial resources and potential need for additional funding through stock offerings, leading to dilution.
Potential: Dependence on the success of NE3107.

BIVI的核心优势是什么？

Promising lead drug candidate (NE3107) in Phase III trials for Alzheimer's disease.
Pipeline of drug candidates targeting multiple diseases.
Experienced management team.
Proprietary drug development platform.

BIVI的劣势是什么？

Clinical-stage company with no currently approved products.
Limited financial resources.
High risk of clinical trial failure.
Small number of employees.

BIVI有哪些机遇？

Partnerships with larger pharmaceutical companies.
Expansion into new therapeutic areas.
Positive clinical trial results for NE3107.
Regulatory approval for NE3107.

BIVI面临哪些威胁？

Competition from other biotechnology companies.
Failure of clinical trials.
Regulatory hurdles.
Dilution of shareholder value through stock offerings.

BIVI的竞争对手是谁？

Artesian Resources Corporation — Utilities sector, unrelated to BioVie's therapeutics. — (ARTL)
Can-Fite BioPharma Ltd — Focuses on autoimmune and inflammatory diseases. — (CANF)
Cero Therapeutics Holdings, Inc. — Developing cell therapies for cancer. — (CERO)
Elanco Animal Health Incorporated — Focuses on animal health products. — (ELAB)
Galmed Pharmaceuticals Ltd. — Developing therapies for liver diseases. — (GLMD)

Key Metrics

Price: $1.40 (+3.70%)
Market Cap: $11.0M
MoonshotScore: 46/100

常见问题

What does BioVie Inc. (BIVI) do?

BioVie Inc. (BIVI) is a clinical-stage biotechnology company focused on developing and commercializing innovative drug therapies. Their primary focus is on treatments for neurodegenerative and liver diseases, as well as certain cancers. The company's lead drug candidate, NE3107, is currently in Phase III clinical trials for Alzheimer's disease and Phase I for Parkinson's disease, while BIV201 has completed Phase IIa trials for ascites due to chronic liver cirrhosis. Additionally, they are exploring NE3107's potential in multiple myeloma and prostate cancer through preclinical studies.

Is BIVI stock a good buy?

BIVI stock presents a high-risk, high-reward investment opportunity. The company's success hinges on the clinical trial outcomes of NE3107, particularly the Phase III trial for Alzheimer's disease. While positive results could lead to significant market gains, failure could negatively impact the stock price. The company's market cap is $0.01B and P/E ratio is -0.61. Investors should carefully consider their risk tolerance and conduct thorough due diligence before investing.

What are the main risks for BIVI?

The main risks for BIVI include the potential failure of clinical trials, particularly for NE3107, which could significantly impact the company's value. Regulatory hurdles and delays in drug approval also pose a risk. As a clinical-stage company, BIVI has limited financial resources and may need to raise additional capital through stock offerings, leading to potential dilution of shareholder value. Competition from other biotechnology companies is also a factor to consider.

What catalysts could move BIVI stock?

Several catalysts could move BIVI stock, including positive results from the Phase III clinical trial of NE3107 for Alzheimer's disease, expected in 2027. Progress in the Phase I clinical trial for NE3107 in Parkinson's disease could also drive positive momentum. Furthermore, any strategic partnerships with larger pharmaceutical companies or regulatory approvals for its drug candidates could serve as significant catalysts. Updates on the pre-clinical development of NE3107 for multiple myeloma and prostate cancer may also influence investor sentiment.

What is BIVI stock price target?

As of March 3, 2026, there is no recent analyst coverage available to provide a consensus price target for BIVI stock. Given its clinical-stage nature and reliance on clinical trial outcomes, a fair value estimate would be highly speculative. Investors should closely monitor clinical trial results and regulatory developments to assess the potential value of BIVI stock. The company's P/E ratio is -0.61.